特発性肺線維症の疫学的予測

◆英語タイトル:EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025
◆商品コード:GDHCER121-16
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月7日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥443,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥886,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,330,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、特発性肺線維症の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・特発性肺線維症の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・特発性肺線維症の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Idiopathic Pulmonary Fibrosis – Epidemiology Forecast to 2025

Summary

The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF is more common in men and the incidence and prevalence of IPF typically increases with advancing age.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.

For this analysis, GlobalData epidemiologists used data from large comprehensive healthcare databases and country-specific studies published in peer-reviewed journals to estimate the diagnosed incident and diagnosed prevalent cases of IPF in addition to sources that provided data for cases confirmed through both biopsy of the lung and HRCT. Diagnosed incident and diagnosed prevalent cases were further segmented by age and sex to provide more detailed characteristics regarding the diseased population. The use of studies with consistent methodology across the 7MM provides a significant measure to compare the underlying burden of IPF across the 7MM. Additionally, GlobalData epidemiologists provided the diagnosed incident and diagnosed prevalent cases of IPF in the 7MM, except Japan, segmented by severity (mild, moderate, and severe) based on GAP index, which can be of importance for predicting the prognosis and course of treatment.

Scope

- The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.
- The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IPF EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IPF therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Epidemiology 8
2.1 Risk Factors and Comorbidities 8
2.2 Global Trends 10
2.2.1 Incidence 10
2.2.2 Prevalence 11
2.3 Forecast Methodology 13
2.3.1 Sources Used 13
2.3.2 Forecast Assumptions and Methods 16
2.3.3 Sources Not Used 24
2.4 Epidemiological Forecast for IPF (2015-2025) 25
2.4.1 Diagnosed Incident Cases 25
2.4.2 Diagnosed Prevalent Cases 32
2.4.3 IPF Mortality 39
2.5 Discussion 44
2.5.1 Epidemiological Forecast Insight 44
2.5.2 Limitations of the Analysis 45
2.5.3 Strengths of the Analysis 46
3 Appendix 47
3.1 Bibliography 47
3.2 About the Authors 50
3.2.1 Epidemiologist 50
3.2.2 Reviewers 50
3.2.3 Global Director of Therapy Analysis and Epidemiology 51
3.2.4 Global Head of Healthcare 52
3.3 About GlobalData 53
3.4 About EpiCast 53
3.5 Disclaimer 54

1.1 List of Tables
Table 1: Risk Factors and Comorbidities of IPF 9
Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IPF 13
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF 14
Table 4: 7MM, except Japan, Sources Used to Forecast Severity Segmentation of Diagnosed Incident Cases and Diagnosed Prevalent Cases of IPF 15
Table 5: 7MM, Sources Used to Forecast IPF Deaths 16
Table 6: 7MM, Sources Not Used in the Epidemiological Analysis of IPF 25
Table 7: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 26
Table 8: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N (Row %), 2015 28
Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, N (Row %), 2015 30
Table 10: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 33
Table 11: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N (Row %), 2015 34
Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, N (Row %), 2015 36
Table 13: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 40
Table 14: 7MM, Age-Specific IPF Deaths, Both Sexes, N (Row %), 2015 41
Table 15: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, N (Row %), 2015 43

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, 2015-2025 27
Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N, 2015 29
Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, 2015 30
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of IPF, Ages ≥18 Years, N, 2015 31
Figure 5: US and 5EU, Diagnosed Incident Cases of IPF by Severity, Both Sexes, Ages ≥18, 2015 32
Figure 6: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 33
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N, 2015 35
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, 2015 37
Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of IPF, Ages ≥18 Years, N, 2015 38
Figure 10: US and 5EU, Diagnosed Prevalent Cases of IPF by Severity, Both Sexes, Ages ≥18 Years, 2015 39
Figure 11: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 40
Figure 12: 7MM, Age-Specific IPF Deaths, Both Sexes, N, 2015 42
Figure 13: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, 2015 44

★調査レポート[特発性肺線維症の疫学的予測]販売に関する免責事項
★調査レポート[特発性肺線維症の疫学的予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆